The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue

BACKGROUND: Erectile dysfunction (ED) is a relatively frequent disease that negatively impacts the overall quality of life, well‐being, and relationships. Although the use of phosphodiesterase 5 inhibitors (PDE5is) has revolutionized the treatment of ED, a high percentage of ED patients discontinue...

Descripción completa

Detalles Bibliográficos
Autores principales: Zucchi, A., Costantini, E., Scroppo, F. I., Silvani, M., Kopa, Z., Illiano, E., Petrillo, M. G., Cari, L., Nocentini, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790582/
https://www.ncbi.nlm.nih.gov/pubmed/31350821
http://dx.doi.org/10.1111/andr.12683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790582/
https://www.ncbi.nlm.nih.gov/pubmed/31350821
http://dx.doi.org/10.1111/andr.12683

Ejemplares similares